4BASEBIO PLC

AGM Information • Oct 10, 2025

National Storage Mechanism | Additional information

4basebio Plc - Result of Extraordinary General Meeting

PR Newswire

LONDON, United Kingdom, October 10

10 October 2025

4basebio PLC

("4basebio" or the "Company")

Result of Extraordinary General Meeting

Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that all of the resolutions proposed at its Extraordinary General Meeting held earlier today were duly passed. 

For further enquiries, please contact:

4basebio PLC	+44 (0)12 2396 7943
Dr. Heikki Lanckriet, CEO
Cairn Financial Advisers LLP (Nominated Adviser )	+44 (0)20 7213 0880
Jo Turner / Sandy Jamieson / Ed Downes
Cavendish Capital Markets Limited ( Joint Broker)	+44 (0)20 7220 0500
Geoff Nash / Nigel Birks
RBC Capital Markets (Joint Broker)	+44 (0) 20 7653 4000
Kathryn Deegan / Matthew Coakes

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused on accelerating the development of advanced therapy medicinal products (ATMPs) through its high-performance synthetic DNA products and non-viral, cell targeting nucleic acid delivery platform. The Company’s objective is to become a market leader in the manufacture and supply of high-quality synthetic DNA products for research, therapeutic and pharmacological use as well as development of target specific non-viral vectors for the efficient delivery of payloads in patients.

---

---